ANI Pharmaceuticals Stock News

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ANIP, NVMI, AZPN, GRNT and CVLG have been added to the Zacks Rank #1 (Strong Buy) List on August 25, 2023.

BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Stren

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wal

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.13 per share a year ago.

ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.

BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 finan

Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.

ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs

Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. The company has a diverse product portfolio and strong relationships in the generic drug ma

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to loss of $0.12 per share a year ago.

ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.